Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program

for the Diabetes Prevention Program Research Group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Antidepressant medication use (ADM) has been shown to predict diabetes. This article assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). Methods: DPP participants randomized to metformin (MET), life-style intervention (ILS), or placebo (PLB) were assessed for depression (Beck Depression Inventory [BDI]) annually, ADM use semiannually, serum inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6]) at baseline and year 1, and diagnosis of type 2 diabetes mellitus (T2DM) semiannually (for 3.2 years). Results: At baseline (N = 3187), M (SD) body mass index was 34 (6) kg/m2 and the median (interquartile range) BDI score was 3 (1-7). One hundred eighty-one (5.7%) reported ADM use and 328 (10%) had BDI scores of 11 or higher. CRP and IL-6 levels did not differ by treatment group. Baseline ADM, but not BDI score, was associated with higher levels of baseline CRP adjusted for demographic, anthropometric variables, and other medications (20% higher, p =.01). Year 1 CRP decreased for non-ADM users in the MET (-13.2%) and ILS (-34%) groups and ADM users in the ILS group (-29%). No associations were found with IL-6. CRP and continuous use of ADM predicted incident T2DM in the PLB group. In the ILS group, continuous and intermittent ADM, but not CRP, predicted T2DM. In the MET group, CRP predicted incident T2DM. CRP did not mediate the risk of T2DM with ADM use in any group. Conclusions: ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM; however, CRP did not significantly mediate the effect of ADM.

Original languageEnglish (US)
Pages (from-to)167-173
Number of pages7
JournalPsychosomatic Medicine
Volume80
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

C-Reactive Protein
Antidepressive Agents
Depression
Type 2 Diabetes Mellitus
Metformin
Interleukin-6
Equipment and Supplies
Placebos
Life Style
Body Mass Index
Biomarkers
Demography

Keywords

  • antidepressant medications
  • depression
  • diabetes
  • inflammatory markers

ASJC Scopus subject areas

  • Applied Psychology
  • Psychiatry and Mental health

Cite this

Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. / for the Diabetes Prevention Program Research Group.

In: Psychosomatic Medicine, Vol. 80, No. 2, 01.02.2018, p. 167-173.

Research output: Contribution to journalArticle

for the Diabetes Prevention Program Research Group. / Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program. In: Psychosomatic Medicine. 2018 ; Vol. 80, No. 2. pp. 167-173.
@article{4c1a881cd37c4533b72cb30cdeebddbb,
title = "Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program",
abstract = "Objective: Antidepressant medication use (ADM) has been shown to predict diabetes. This article assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). Methods: DPP participants randomized to metformin (MET), life-style intervention (ILS), or placebo (PLB) were assessed for depression (Beck Depression Inventory [BDI]) annually, ADM use semiannually, serum inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6]) at baseline and year 1, and diagnosis of type 2 diabetes mellitus (T2DM) semiannually (for 3.2 years). Results: At baseline (N = 3187), M (SD) body mass index was 34 (6) kg/m2 and the median (interquartile range) BDI score was 3 (1-7). One hundred eighty-one (5.7{\%}) reported ADM use and 328 (10{\%}) had BDI scores of 11 or higher. CRP and IL-6 levels did not differ by treatment group. Baseline ADM, but not BDI score, was associated with higher levels of baseline CRP adjusted for demographic, anthropometric variables, and other medications (20{\%} higher, p =.01). Year 1 CRP decreased for non-ADM users in the MET (-13.2{\%}) and ILS (-34{\%}) groups and ADM users in the ILS group (-29{\%}). No associations were found with IL-6. CRP and continuous use of ADM predicted incident T2DM in the PLB group. In the ILS group, continuous and intermittent ADM, but not CRP, predicted T2DM. In the MET group, CRP predicted incident T2DM. CRP did not mediate the risk of T2DM with ADM use in any group. Conclusions: ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM; however, CRP did not significantly mediate the effect of ADM.",
keywords = "antidepressant medications, depression, diabetes, inflammatory markers",
author = "{for the Diabetes Prevention Program Research Group} and {de Groot}, Mary and David Marrero and Lisa Mele and Todd Doyle and Frank Schwartz and Kieren Mather and Ronald Goldberg and Price, {David W.} and Yong Ma and Knowler, {William C.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1097/PSY.0000000000000535",
language = "English (US)",
volume = "80",
pages = "167--173",
journal = "Psychosomatic Medicine",
issn = "0033-3174",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Depressive Symptoms, Antidepressant Medication Use, and Inflammatory Markers in the Diabetes Prevention Program

AU - for the Diabetes Prevention Program Research Group

AU - de Groot, Mary

AU - Marrero, David

AU - Mele, Lisa

AU - Doyle, Todd

AU - Schwartz, Frank

AU - Mather, Kieren

AU - Goldberg, Ronald

AU - Price, David W.

AU - Ma, Yong

AU - Knowler, William C.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Objective: Antidepressant medication use (ADM) has been shown to predict diabetes. This article assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). Methods: DPP participants randomized to metformin (MET), life-style intervention (ILS), or placebo (PLB) were assessed for depression (Beck Depression Inventory [BDI]) annually, ADM use semiannually, serum inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6]) at baseline and year 1, and diagnosis of type 2 diabetes mellitus (T2DM) semiannually (for 3.2 years). Results: At baseline (N = 3187), M (SD) body mass index was 34 (6) kg/m2 and the median (interquartile range) BDI score was 3 (1-7). One hundred eighty-one (5.7%) reported ADM use and 328 (10%) had BDI scores of 11 or higher. CRP and IL-6 levels did not differ by treatment group. Baseline ADM, but not BDI score, was associated with higher levels of baseline CRP adjusted for demographic, anthropometric variables, and other medications (20% higher, p =.01). Year 1 CRP decreased for non-ADM users in the MET (-13.2%) and ILS (-34%) groups and ADM users in the ILS group (-29%). No associations were found with IL-6. CRP and continuous use of ADM predicted incident T2DM in the PLB group. In the ILS group, continuous and intermittent ADM, but not CRP, predicted T2DM. In the MET group, CRP predicted incident T2DM. CRP did not mediate the risk of T2DM with ADM use in any group. Conclusions: ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM; however, CRP did not significantly mediate the effect of ADM.

AB - Objective: Antidepressant medication use (ADM) has been shown to predict diabetes. This article assessed the role of inflammatory markers in this relationship within the Diabetes Prevention Program (DPP). Methods: DPP participants randomized to metformin (MET), life-style intervention (ILS), or placebo (PLB) were assessed for depression (Beck Depression Inventory [BDI]) annually, ADM use semiannually, serum inflammatory markers (C-reactive protein [CRP], interleukin 6 [IL-6]) at baseline and year 1, and diagnosis of type 2 diabetes mellitus (T2DM) semiannually (for 3.2 years). Results: At baseline (N = 3187), M (SD) body mass index was 34 (6) kg/m2 and the median (interquartile range) BDI score was 3 (1-7). One hundred eighty-one (5.7%) reported ADM use and 328 (10%) had BDI scores of 11 or higher. CRP and IL-6 levels did not differ by treatment group. Baseline ADM, but not BDI score, was associated with higher levels of baseline CRP adjusted for demographic, anthropometric variables, and other medications (20% higher, p =.01). Year 1 CRP decreased for non-ADM users in the MET (-13.2%) and ILS (-34%) groups and ADM users in the ILS group (-29%). No associations were found with IL-6. CRP and continuous use of ADM predicted incident T2DM in the PLB group. In the ILS group, continuous and intermittent ADM, but not CRP, predicted T2DM. In the MET group, CRP predicted incident T2DM. CRP did not mediate the risk of T2DM with ADM use in any group. Conclusions: ADM was significantly associated with elevated CRP and incident T2DM. In the PLB group, ADM and CRP independently predicted onset of T2DM; however, CRP did not significantly mediate the effect of ADM.

KW - antidepressant medications

KW - depression

KW - diabetes

KW - inflammatory markers

UR - http://www.scopus.com/inward/record.url?scp=85041706560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041706560&partnerID=8YFLogxK

U2 - 10.1097/PSY.0000000000000535

DO - 10.1097/PSY.0000000000000535

M3 - Article

C2 - 29016549

AN - SCOPUS:85041706560

VL - 80

SP - 167

EP - 173

JO - Psychosomatic Medicine

JF - Psychosomatic Medicine

SN - 0033-3174

IS - 2

ER -